McKenna's Pharmacology for Nursing, 2e

984

Index

Hydroxyurea, 222, 775, 777, 787, 789–790 Hydroxyzine, 853, 854 Hyoscine, 501, 503, 927 Hyoscyamine, 501, 503 Hyperaldosteronism, 803, 813 Hypercalcaemia, 551, 554, 563, 564 Hyperglycaemia, 36–37, 572, 578 Hyperkalaemia, 37, 803 Hyperlipidaemia, 729, 730, 733 treating, 734–735 Hyperparathyroidism, 551, 563–564 secondary, 564 pulmonary arterial, 664 treating, 662, 664, 667 initiating therapy, 672–674 safe medication administration, 671 “white coat”, 661 Hyperthyroidism, 551, 555, 556 Hypertonia, 385, 388 Hypertonic solution, 77 Hypnosis, 303, 305 Hypnotic agents. See Anxiolytic and hypnotic agents Hypocalcaemia, 551, 554, 563–569 Hypoglycaemia, 36, 572, 578 Hypogonadism, 627, 629 Hypokalaemia, 37, 809 Hypoparathyroidism, 551, 563–569 Hypopituitarism, 521, 525 Hypotension, 652, 657, 661–662 Hypothalamic and pituitary agents, 521–534 adults, 523 agonists, 521, 523 children, 523 drugs affecting anterior pituitary hormones, 521, 525–530 growth hormone agonists. See Growth hormone agonists growth hormone antagonists. See Growth hormone antagonists drugs affecting hypothalamic hormones, 521, 522–525 adverse effects, 524 care considerations, 524 contraindications and cautions, 524 pharmacokinetics, 524 therapeutic actions and indications, 523–524 drugs affecting posterior pituitary hormones, 521, 530–533 adverse effects, 533 care considerations, 533 contraindications and cautions, 532–533 drug–drug interactions, 533 pharmacokinetics, 532 therapeutic actions and indications, 530 older adults, 523 Hypersensitivity, 31, 33 anti-infective agents, 87 Hypertension, 652, 660–661 antihypertensive agents. See Antihypertensive agents

Hypothalamic hormones, 516 agonists, 524 antagonists, 524 drugs affecting, 521, 522–525 adverse effects, 524 care considerations, 524 contraindications and cautions, 524 pharmacokinetics, 524 therapeutic actions and indications, 523–524 Hypothalamic–pituitary axis (HPA), 512, 517 Hypothalamus, 512, 514–515 Hypothyroidism, 551, 554–556 critical thinking scenario, 558–560 Hypotonic solution, 77 Hyssop, 965 I Iatrogenesis, 31, 39 Ibandronate, 566, 567 Ibuprofen, 241, 247, 250 Idarubicin, 205, 206 Ifosfamide, 195, 197 Imatinib, 191, 194, 219–222 Imipramine, 316, 317, 318, 320, 321 Imiquimod, 146, 147, 951 Immune modulators, 258–269 adults, 260 children, 260 immune stimulants, 258, 259–261 care considerations, 262–263 interferons. See Interferons interleukins. See Interleukins immune suppressants, 258, 263–266 monoclonal antibodies, 258, 263–267 T- and B-cell suppressors, 263–266 older adults, 260 sites of action, 259 Immune response and inflammation, 228–238 barrier defences, 229–230 gastric acid, 229 major histocompatibility complex, 228, 229–230 mucous membranes, 229 skin, 229 cellular defences, 230–231 basophils, 230 eosinophils, 230 lymphoid tissues, 231 monocytes/macrophages, 228, 230–231 neutrophils, 230 immune response, 233–235 antibody formation, 234–235 B cells, 233–234 complement proteins, 234 interferons, 235 interleukins, 235 T cells, 233–234 thymosin, 235 tumour necrosis factor (TNF), 235 inflammatory response, 231–233 anakinra, 253–255, 264, 266 care considerations, 267–268

chemotaxis, 231–232 clinical presentation, 232–233 histamine release, 231 kinin system, 231 interrelationship, 235–237 pathophysiology, immune system, 237–238 autoimmune disease, 238 neoplasms, 237–238

transplant rejection, 238 viral invasion of cells, 238 Immune sera, 272, 285–288 adverse effects, 287 care considerations, 287–288 contraindications and cautions, 287 drug-drug interactions, 287 immunoglobulin, normal, 273, 286, 287 pharmacokinetics, 285 therapeutic actions and indications, 285 Immune stimulants, 258, 259–261 interferons. See Interferons interleukins. See Interleukins Immune suppressants, 258, 263–267 monoclonal antibodies, 258, 263–266 T- and B-cell suppressors, 263–266 Immune system drugs acting on anti-inflammatory, antiarthritis and related agents. See Anti- inflammatory, antiarthritis and related agents immune modulators. See Immune modulators vaccines and sera. See Vaccines and sera pathophysiology involving the immune system, 237–238 autoimmune disease, 238 neoplasms, 237–238 National Schedules Australia, 275–276 New Zealand, 277 paediatric, 278 Immunity, 273 Immunoglobulin. See Immune sera Immunological factors drug effects and, 25, 26–27 Impinem-cilastin, 97, 98 Implementation, 42, 45 Incretins, 572, 573, 574, 575, 587, 588 Indacaterol, 867, 871–872 Indapamide, 675, 805, 807 Indinavir, 136, 139 Indomethacin, 241, 247 Induction, 416, 419 Infiltration, anaesthesia, 424 Inflammation. See also Immune response and inflammation inflammatory response, 231–233, 240 chemotaxis, 231–232 anakinra, 253–255, 264, 265 care considerations, 267–268 transplant rejection, 238 viral invasion of cells, 238 Immunisation, 272, 273–278